Merck
Pays $400 Million In National Medicaid Fraud Settlement;
New Investigation
Model Ends Seven-Year Qui Tam Whistleblower Case

Home

Medicaid & The States

About
Medicaid

Rebate
Act & Best Price

How
Best Price Is Reported

The Case

Our News Release

Introduction

The
Company

The
Nevada Case

The Allegations

MD
Kickbacks

Consultant
Meetings

Free
Drug Kickbacks

Best
Price

The New
Model

The Attorneys

Steven
Cohen

Mark
Kleiman

BethAnne
Yeager

Timeline: A
Seven-Year Ordeal

Federal Case Documents

EDPA Complaint

EDPA Settlement Agreement

EDPA CIA

EDPA Orders

EDPA Notice of Intervention

EDPA Stipulation of Dismissal

The Drugs

The Drugs

Drug
Expert Greg Hamilton, Sr.

Whistleblowers

$20
Billion-Plus Recovered

Federal,
State and Local Laws

Industries,
Goods & Services

News & Info

Our News Release

USDOJ Release

EDPA Release

States

Company

Other News and
Blogs

Glossary

Taxpayers Against Fraud

About Taxpayers
Against Fraud

Our
Attorneys & TAF

TAF Web site

The Drugs

Throughout the drugfraudsettlement.com Web site there is mention that
this case against Merck involved its drugs Vioxx®, the discontinued
arthritis drug, and Zocor®, a statin, which lost its patent protection in
2006.

However, as alleged in the federal case, Merck employed its illegal
marketing practices (MD
Kickbacks, Consultant
Meetings) to promote several other drugs, including Cozaar®, Fosamax®,
Maxalt®, and Singulair®.

This table briefly describes each of these Merck products:

Merck Drug

Primary Purpose

Nature of Condition

Cozaar®

Reduce high blood pressure

Chronic

Fosamax®

Prevent loss of bone density

Chronic

Maxalt®

Treat migraine headaches

Acute

Singulair®

Control asthma and reduce asthma attacks

Chronic

Vioxx®

Treat arthritis and joint pain

Chronic

Zocor®

Reduce risk of heart disease

Chronic

Contact PRforLAW, LLC
| Legal Notices and
Disclaimers

©
Copyright 2008 PRforLAW.
LLC. All rights reserved. This Web site and any of its pages may not be
copied, electronically stored or deep linked without written permission from us.
In the case of material we have reprinted with permission, contact the copyright
holder of that document/work. Inactive links represent expected data not yet
received.